Form 4: Unicycive Therapeutics Executive Granted Significant Stock Options

Pramod Gupta, EVP of Pharmaceuticals and BD at Unicycive Therapeutics, was granted 90,000 stock options with an exercise price of $4.71.

Summary

• Pramod Gupta, Executive Vice President of Pharmaceuticals and Business Development at Unicycive Therapeutics, Inc. (UNCY), was granted 90,000 stock options.
• The options have an exercise price of $4.71 per share.
• The transaction date for these options was July 28, 2025.
• Following this transaction, Pramod Gupta beneficially owns a total of 301,986 derivative securities.
• The options begin vesting on July 28, 2026, with 22,500 options vesting on that date.
• The remaining options will vest at a rate of 1/36th per month thereafter.
• The options expire on July 28, 2035.

Sentiment

Score: 6

Explanation: The filing reports a standard executive compensation event (grant of stock options), which is generally a neutral to slightly positive signal as it aligns executive incentives with shareholder value. It does not contain information about financial performance or strategic shifts that would significantly alter sentiment.

Positives

• The grant of 90,000 stock options to a key executive (EVP, Pharmaceuticals and BD) aligns management incentives with shareholder value.
• The options have a long expiration date of July 28, 2035, providing a long-term incentive for the executive.

Future Outlook

The vesting schedule for the granted stock options extends through July 28, 2026, and monthly thereafter, indicating a long-term incentive structure for the executive.

Industry Context

This Form 4 filing reports a standard executive compensation event within the pharmaceutical and biotechnology industry, where stock options are a common tool to incentivize and retain key personnel, aligning their interests with long-term company performance.

Comparison to Industry Standards

• The grant of stock options to a senior executive like an EVP is a common practice in the pharmaceutical and biotechnology sectors, comparable to compensation structures seen at companies such as Moderna, Pfizer, or Gilead Sciences, which frequently use equity-based incentives to attract and retain talent.
• The specific number of options and exercise price would need to be benchmarked against peer companies of similar market capitalization and stage of development to assess if it is above, below, or in line with industry averages for executives in similar roles.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive can align management's long-term interests with shareholder value, potentially leading to improved company performance.
• Employees: This filing specifically relates to executive compensation and does not directly impact the broader employee base, though it reflects the company's compensation practices for senior roles.

Next Steps

• The stock options will begin vesting on July 28, 2026, with subsequent monthly vesting, leading up to their expiration on July 28, 2035.

Key Dates

Keywords

Unicycive Therapeutics, UNCY, Stock Options, Pramod Gupta, Insider Transaction, Form 4, Executive Compensation, Pharmaceuticals, Biotechnology